Apr 02, 2022
Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase I Clinical Trial of CB06
Dec 17, 2021
Zhimeng Biopharma Announces FDA Approval of its Investigational New Drug (IND) Application for CB06-036
Nov 12, 2021
Apr 02, 2022
Dec 17, 2021
Nov 12, 2021